LXEO (STOCKS)
Lexeo Therapeutics, Inc. Common Stock
$6.380000
+0.400000 (+6.69%)
Prev close: $5.980000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- R. Nolan Townsend
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $473.42M
- Employees
- 75
- P/E (TTM)
- -2.73
- P/B (TTM)
- 1.77
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.27 | $-0.32 | +0.0508 | +15.84% |
|
Sep 2025 (Q3)
|
$-0.33 | $-0.53 | +0.2004 | +37.78% |
|
Jun 2025 (Q2)
|
$-0.60 | $-0.69 | +0.0936 | +13.49% |
|
Mar 2025 (Q1)
|
$-0.99 | $-0.80 | -0.1910 | -23.90% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $9.30M |
| Operating Expenses | $109.26M |
| Depreciation and Amortization | $268.00K |
| Research and Development | $63.80M |
| Other Operating Expenses | $45.19M |
| Operating Income/Loss | -$109.26M |
| Income/Loss From Continuing Operations After Tax | -$99.67M |
| Income/Loss From Continuing Operations Before Tax | -$99.67M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$99.96M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$99.96M |
| Net Income/Loss Available To Common Stockholders, Basic | -$99.96M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.86 |
| Diluted Earnings Per Share | -$1.86 |
| Basic Average Shares | 53,645,323 |
| Diluted Average Shares | 53,645,323 |
| Assets | $268.69M |
| Current Assets | $188.39M |
| Noncurrent Assets | $80.30M |
| Fixed Assets | $1.14M |
| Other Non-current Assets | $79.16M |
| Liabilities | $22.02M |
| Current Liabilities | $16.81M |
| Accounts Payable | $4.86M |
| Other Current Liabilities | $11.95M |
| Noncurrent Liabilities | $5.21M |
| Equity | $246.67M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $246.67M |
| Liabilities And Equity | $268.69M |
| Net Cash Flow From Operating Activities | -$98.56M |
| Net Cash Flow From Operating Activities, Continuing | -$98.56M |
| Net Cash Flow From Investing Activities | -$90.25M |
| Net Cash Flow From Investing Activities, Continuing | -$90.25M |
| Net Cash Flow From Financing Activities | $216.80M |
| Net Cash Flow From Financing Activities, Continuing | $216.80M |
| Net Cash Flow | $27.98M |
| Net Cash Flow, Continuing | $27.98M |
| Comprehensive Income/Loss | -$99.67M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$99.67M |
| Other Comprehensive Income/Loss | $291.00K |